Mark Hill
- Oncology top 0.5%
- Colorectal Cancer Treatments and Studies 36
- Colorectal Cancer Surgical Treatments 13
- Cancer Treatment and Pharmacology 13
-
- Gastric Cancer Management and Outcomes 21
- Lung Cancer Treatments and Mutations 8
-
- Lymphoma Diagnosis and Treatment 11
- Health top 2%
- Surgery top 2%
- Colorectal and Anal Carcinomas 14
- Esophageal Cancer Research and Treatment 9
- Co-authors
- David CunninghamA. NormanSamuel H. PrestonIra RosenwaikeTimothy PriceIan ChauPaul J. RossHans‐Joachim Schmoll
- Journals
- Journal of Clinical Oncology (15 papers)British Journal of Cancer (14 papers)European Journal of Cancer (10 papers)
- Partner nations
- United KingdomUnited StatesAustralia
In The Last Decade
Mark Hill
107 papers receiving 5.1k citations
Hit Papers
Peers
Comparison fields: 5 of 155
- Oncology 3.0k
- Pulmonary and Respiratory Medicine 1.5k
- Pathology and Forensic Medicine 744
- Health 347
- Surgery 1.5k
Countries citing papers authored by Mark Hill
This map shows the geographic impact of Mark Hill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Hill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Hill more than expected).
Fields of papers citing papers by Mark Hill
This network shows the impact of papers produced by Mark Hill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Hill. The network helps show where Mark Hill may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark Hill, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 7 | |
| 2 | 2020 | 7 | |
| 3 | 2019 | 1 | |
| 4 | 2013 | 19 | |
| 5 | 2012 | 1 | |
| 6 | Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancerbreakdown → | 2011 | 533 |
| 7 | 2009 | 3 | |
| 8 | 2005 | 14 | |
| 9 | 2005 | 135 | |
| 10 | 2003 | 28 | |
| 11 | 2003 | 9 | |
| 12 | 2003 | 48 | |
| 13 | 2003 | 11 | |
| 14 | 2003 | 3 | |
| 15 | 2002 | 33 | |
| 16 | 2002 | 9 | |
| 17 | 2001 | 51 | |
| 18 | 1999 | 23 | |
| 19 | 1995 | 37 | |
| 20 | A treatable form of dementia due to normal-pressure, communicating hydrocephalus. | 1967 | 30 |
About Mark Hill
Mark Hill is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Health, having authored 107 papers that have together received 5.4k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (36 papers), Gastric Cancer Management and Outcomes (21 papers), Colorectal and Anal Carcinomas (14 papers), Colorectal Cancer Surgical Treatments (13 papers), Cancer Treatment and Pharmacology (13 papers), Lymphoma Diagnosis and Treatment (11 papers), Esophageal Cancer Research and Treatment (9 papers) and Lung Cancer Treatments and Mutations (8 papers). The work is most often cited by research in Oncology (3.0k citations), Pulmonary and Respiratory Medicine (1.5k citations) and Pathology and Forensic Medicine (744 citations). Mark Hill has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include David Cunningham, A. Norman, Samuel H. Preston, Ira Rosenwaike, Timothy Price, Ian Chau, Paul J. Ross, Hans‐Joachim Schmoll, Jean A. Maroun and Daniel G. Haller. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Cancer, European Journal of Cancer, Annals of Oncology and Social Forces.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.